DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine) (14:0 PC) Cat. No. #IAX-700-400

Name: DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine) (14:0 PC) Cat. No. #IAX-700-400 - 5 x 50 mg, VAT Exempt
Brand: Innaxon
SKU: IAX-700-400-5050
Price: 168.00 GBP
Availability: InStock

• A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecular annulus.

• Lipodisq^TM polymers are available as 4 defined structures (1:1, 2:1, 3:1 and 4:1 Styrene to Maleic Acid (SMA) rations) each individually operational within a selected pH range for optimal working conditions.

• Components are batch-tested for Lipodisq^TM formation using buffer systems available, which are tested for nano-formulated drug analysis by Dynamic Light Scattering (DLS). These buffer solutions are endotoxin-tested and sterile.

• Lipodisq^TM formation is highly efficient and nanodiscs show a good safety profile and are suitable for in vitro and in vivo (in experimental animals) investigations.

£42.00

Description Features Resources

Molecular Formula	C₃₆H₇₂NO₈P
Size	50mg / 1g
MW	677.9
CAS	18194-24-6
Purity	>98%
Application	1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) is a synthetic phospholipid utilized in liposomes and lipid bilayers for the study of biological membranes. Its utility extends to investigating the influence of lipids on enzymatic activity and protein function when formulated into nanodiscs, LNP or liposomes. Phosphatidylcholines are zwitterionic phospholipids containing choline as part of the polar head group. At physiological pH, phosphocholine has an overall neutral charge. Furthermore, this compound has proven valuable in exploring the interplay between lipids and proteins, elucidating their interactions, and unraveling the impact of lipids on protein structure and functionality.
Formulation	Lipodisq^TM are nanosized lipid-based discoidal particles that can be manufactured with P(SMA) and lipids such as DMPC (1,2-Dimyristoyl-sn-glycero-3-phosphocholine) (14:0 PC) (DMPC: IAX-700-400) to incorporate hydrophobic, poorly water-soluble active compounds, such as peptides, lipids, lipoproteins, transmembrane proteins and glycolipids. Applications of Lipodisq^TM include functional and structural characterisation of the cargo and drug delivery with improved bioavailability, and biological half-life in vivo (PD/PK) or delivery of antigens preserved in their native conformation for immunization purposes.
Appearance	White powder
Handling	Keep dry. Avoid skin and eye contact.
Shipping	Blue Ice or ambient
Storage	-15-25°C
Stability	Upon receipt, store product at -15-25°C. In its unopened original vial, the product is stable for at least 24 months when stored at -15-25°C. Once the glass vial is opened, or an emulsion is prepared in sterile, endotoxin-free ddWater (IAX-900-902) and aliquoted into sterile vials under sterile conditions, the lipid emulsion (e.g. at 2.5%) remains stable for an additional one week when stored at 2-8°C and kept sterile.
Solubility	Insoluble in water and DMSO. Soluble in Ethanol, Methanol and Chloroform

Lipodisq^TM Technology

A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilised by a chaperone molecule annulus.
Internal properties of the phospholipid membrane support the disposition and stabilisation of drug molecule candidates and preserve the native conformation of membrane molecules.
The resulting encapsulated actives are rendered water-soluble and specialised for intra-cellular penetration/delivery via endosomal uptake mechanisms.
Lipodisq^TM solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
For a customizable biodegradable Lipodisq^TM version with a higher concentration of actives or an alternative lipid option, contact Innaxon.

Innaxon as the supplier also welcomes BULK enquiries for this product.

Legal Claim
The Lipodisq^TM technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending.

The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.

Authorized Uses & Restrictions
The purchase of Innaxon product(s) conveys to the buyer the non-transferable right to use the purchased amount of the product and all replicates and derivatives for, internal, non-profit research purposes. The buyer cannot sell, resale or otherwise transfer (a) the product (b) its components or (c) materials made using this product or its components to a third party. The buyer agrees that any activity undertaken with the product and replicates or derivatives will be conducted in compliance with all applicable guidelines, aws, and regulations. The buyer agrees that the product and replicates or derivatives will not be used for any animal or human therapeutic or diagnostic use.

Limited Use License
Purchase does not include any other right or license to use, develop or otherwise exploit our products. Any use of Innaxon products outside of the Authorized Uses requires additional rights from the Licensor.

Download Product Resources

Product Data Sheet
Safety Data Sheet (available upon request)